LON:DEST Destiny Pharma (DEST) Share Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free DEST Stock Alerts GBX 18.25 0.00 (0.00%) (As of 04/17/2024 09:19 PM ET) Add Compare Share Share Today's Range 18▼ 18.4450-Day Range 17.50▼ 4652-Week Range 16.50▼ 84Volume224,600 shsAverage Volume416,073 shsMarket Capitalization£17.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Destiny Pharma alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Destiny Pharma Stock (LON:DEST)Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.Read More DEST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DEST Stock News HeadlinesApril 8, 2024 | usatoday.comCarol Ann Langford’s Legacy of Servant Leadership Informs Her Mission to Nurture Human InnovationApril 3, 2024 | msn.comMarcelo Weigandt opens up on Messi, Maradona, Inter Miami and why he wears No. 57April 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 28, 2024 | msn.com'Lefties losing it': Dr Jordan Peterson gives 'masterclass in lefty annihilation'March 20, 2024 | nytimes.comOprah, Ozempic and UsMarch 18, 2024 | bizjournals.comNKU College of Law, UK College of Medicine plan $150M riverfront facility in CovingtonMarch 16, 2024 | msn.comHolding up half the skyMarch 15, 2024 | msn.comIndia Mobilizes Aid Amid Haiti’s Gang Violence: 24-Hour Helpline and Evacuation Plans in MotionApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 12, 2024 | msn.comRBI goes after ‘peer to peer’ transactions – Cred, NoBroker on radarMarch 11, 2024 | msn.comUR's New Vaccinology Programme Is a Step in the Right DirectionMarch 8, 2024 | abcnews.go.com'I believe in America': Fired-up Biden uses State of the Union to skewer GOP, his 'predecessor'March 8, 2024 | nytimes.comAn Instant Crush Over Mashed PotatoesMarch 6, 2024 | bizjournals.comBayer CEO on how he plans to fix a 'broken' companyFebruary 23, 2024 | dailymail.co.ukITV orders a drama depicting the contaminated blood scandal after Mr Bates Vs The Post Office sparked nationwide uproarFebruary 22, 2024 | morningstar.comDestiny Pharma PLC DESTFebruary 19, 2024 | msn.comHow George Washington can save Israel, and NetanyahuFebruary 18, 2024 | msn.comRFK Jr. has a distinct appeal when it comes to young male votersFebruary 9, 2024 | benzinga.comDestiny Pharma Stock (OTC:DTTYF), Analyst Ratings, Price Targets, PredictionsFebruary 6, 2024 | msn.comHarsh Goenka's vision: India needs to rediscover and recover its old mojoFebruary 4, 2024 | msn.comWant to live forever? The longevity doctor will see you now…February 2, 2024 | msn.comIs it safe to take the weight-loss drug Wegovy for years or maybe forever? Doctors weigh inJanuary 31, 2024 | lse.co.ukDestiny Pharma. Share ChatJanuary 11, 2024 | msn.comBethesda’s Indiana Jones Game May Finally Have A NameJanuary 8, 2024 | msn.comSMALL CAPS IDEAS: Race to diffuse $1trillion healthcare timebombJanuary 8, 2024 | msn.comSMALL CAPS IDEA: Destiny Pharma playing its part in the race to diffuse deadly $1trillion healthcare timebombJanuary 6, 2024 | msn.comIn honor of public servants: The case for making Jan. 6 a national holidaySee More Headlines Receive DEST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Destiny Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/17/2020Today4/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:DEST CUSIPN/A CIKN/A Webwww.destinypharma.com Phone+44-1273-704440FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.87% Return on Assets-36.69% Debt Debt-to-Equity RatioN/A Current Ratio9.48 Quick Ratio11.10 Sales & Book Value Annual Sales£135,028.00 Price / Sales128.82 Cash FlowGBX 6.78 per share Price / Cash Flow2.69 Book ValueGBX 14 per share Price / Book1.30Miscellaneous Outstanding Shares95,310,000Free FloatN/AMarket Cap£17.39 million OptionableNot Optionable Beta0.27 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. William Guy Love (Age 62)Founder, Chief Scientific Officer & Director Comp: $265kMr. Shaun Claydon ACA (Age 56)CFO, Company Secretary & Director Comp: $286kDr. Debra Barker M.D. (Age 62)MSc., Interim CMO & Senior Independent Director Comp: $41kMr. Christopher John Tovey BSc (Age 59)CEO & Director Key CompetitorsOptiBiotix HealthLON:OPTIOxford BioDynamicsLON:OBDOncimmuneLON:ONCSkinBioTherapeuticsLON:SBTXOndine BiomedicalLON:OBIView All CompetitorsInsidersNick RodgersBought 49,477 shares on 5/25/2023Total: £1.53 M ($31.00/share)View All Insider Transactions DEST Stock Analysis - Frequently Asked Questions How have DEST shares performed in 2024? Destiny Pharma's stock was trading at GBX 70 on January 1st, 2024. Since then, DEST stock has decreased by 73.9% and is now trading at GBX 18.25. View the best growth stocks for 2024 here. How were Destiny Pharma's earnings last quarter? Destiny Pharma plc (LON:DEST) announced its earnings results on Thursday, September, 17th. The company reported ($5.50) earnings per share (EPS) for the quarter. What other stocks do shareholders of Destiny Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Dynavax Technologies (DVAX), AFPO.L (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB) and EQTEC (EQT). How do I buy shares of Destiny Pharma? Shares of DEST stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DEST) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeUrgent alert: open this for a huge profit potentialTimothy SykesBiden out June 13; Kamala won’t replace him?Paradigm PressYour Money is Not SafeAmerican AlternativeOptions trading has suddenly become more reliable.Eagle PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Destiny Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.